Healthcare · Pharmaceuticals & Biotechnology
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.The company operates in multiple international markets including the United States, Japan, Europe, and Australia..
Source: Wikipedia
| Fiscal year | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Total income (before exceptional items) | 19,825† | 17,142† | 14,774† | 11,353† | 11,923† |
| Net profit | 6,367 | 3,973 | 2,326 | 425 | -189† |
₹ Crore. † Summed from the four quarterly filings of that fiscal year.
Current board roster from exchange filings. Director remuneration is not in our data, so it isn't shown.
| Name | Designation | Term end |
|---|---|---|
| Nilesh D. Gupta | Executive Director | June 30, 2026 |
| Ramesh Swaminathan | Executive Director | June 30, 2026 |
| Vinita Gupta | Executive Director | June 30, 2026 |
| Alfonso Zulueta | Independent Director | June 30, 2026 |
| Anand Kripalu | Independent Director | June 30, 2026 |
| Jeffrey Kindler | Independent Director | June 30, 2026 |
| Kanwar Bir Singh Anand | Independent Director | June 30, 2026 |
| Mark D. McDade | Independent Director | June 30, 2026 |
| Punita Lal | Independent Director | June 30, 2026 |
| Manju D. Gupta | Non-Executive Director | June 30, 2026 |
Key management names, their remuneration, subsidiaries and brand listings are not in the exchange filings we ingest yet, so they are not shown here rather than estimated.
